Drug profile · INN
eribulin mesylate
ERIBULIN MESYLATE
eribulin mesylate (ERIBULIN MESYLATE) is a tubulin inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — eribulin mesylate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
eribulin mesylate (ERIBULIN MESYLATE) is a tubulin inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Tubulin inhibitor
Primary target: Tubulin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eribulin mesylate?
eribulin mesylate (ERIBULIN MESYLATE) is a tubulin inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for eribulin mesylate?
ERIBULIN MESYLATE is a marketed brand name for eribulin mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eribulin mesylate?
eribulin mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.